MedTrace Logo

Pegfilgrastim PBPC Mobilization Study

NCT00066092 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2008-02-28

No results posted yet for this study

Summary

This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.

Conditions

Interventions

DRUG

pegfilgrastim 12 mg

Pegfilgrastim 12 mg given once for PBPC mobilization

DRUG

filgrastim

Filgrastim given daily for PBPC mobilization

DRUG

pegfilgrastim 6 mg

Pegfilgrastim 6 mg given once for PBPC mobilization

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2004-03-31
Completion
2004-10-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00066092 on ClinicalTrials.gov